Conclusion
With increase in the incidence and spectrum of invasive fungal infections, antifungal drug resistance has become an important consideration in the management of patients. Though unlike bacteria, the level of resistance to antifungal agents is relatively low due to the possible absence of drug-resistant plasmid or transposons in fungi, the recently conducted experiment of horizontal gene transfer in pathogenic Fusarium species shows that there is no scope of complacency. The emergence of intrinsically resistant fungal species as a human pathogen is compounding the challenge of planning treatment strategies. Beyond these confounding factors, the conditions leading to clinical resistance should be kept in mind while managing invasive fungal infections in immunocompromised patients.
Acknowledgement
The author acknowledges the help of M. Manpreet Dhaliwal for organizing the references.